Compositions and Methods for Enhancing Wnt Signaling for Treating Cancer
Summary
USPTO published patent application US20260091038A1 on April 2, 2026, disclosing compositions and methods for enhancing Wnt signaling pathway activities for treating cancer, particularly cancers with APC gene mutations. The application covers pharmaceutical compositions containing GSK-3 inhibitors, preferably LY2090314, encapsulated in nanoparticles. Inventors are George Eng, Omer Yilmaz, and Jonathan Braverman. Application number 19294146 was filed August 7, 2025.
What changed
The USPTO published patent application US20260091038A1 disclosing pharmaceutical compositions and methods for enhancing Wnt signaling pathway activity in cancer treatment. The application specifically covers GSK-3 inhibitors, particularly LY2090314, encapsulated within or associated with nanoparticles for treating cancers with APC gene mutations. The compositions are designed to reduce cancer cell proliferation without affecting normal healthy cell viability. This represents a new patent filing in the oncology therapeutics space covering novel drug delivery formulations.\n\nThis is a published patent application, not a granted patent, and creates no compliance obligations. Healthcare providers, pharmaceutical companies, and investors conducting freedom-to-operate analyses or licensing assessments should review the claims upon grant. The application is pending examination and does not currently confer any exclusive rights.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER
Application US20260091038A1 Kind: A1 Apr 02, 2026
Inventors
George Eng, Omer Yilmaz, Jonathan Braverman
Abstract
Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.
CPC Classifications
A61K 31/5517 A61K 31/497 A61K 31/5377 A61K 38/1709 A61K 45/06 A61P 1/00 A61P 35/00 C07K 14/475
Filing Date
2025-08-07
Application No.
19294146
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.